GLIMMER-01

bisialidase fusion protein · Palleon Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GLIMMER-01, covering 2025-08-20 to 2025-08-20. Get the full timeline:

Most recent: Clinical Trial Update: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) [Phase 1, Phase 2]